Tag: biomedical
-
Vaccine Patch Shown Safe, Produces Measles/Rubella Antibodies
A vaccine delivered with a patch device is shown in a clinical trial to generate neutralizing antibodies against measles and rubella similar to conventional injections.
-
Academic, Industry Labs to Build Brain Cell Models
Researchers from university labs in the U.K. are developing models of brain cell interactions using a company’s synthetic human cells derived from stem cells.
-
Lab-Grown Tissue Company Gains $38M in Seed Funds
A company producing tissue samples in the lab, for drug discovery and preclinical research with robotics and artificial intelligence, raised $38 million in seed funding.
-
Challenge Seeks Precise Addiction Strategies, Biomarkers, Treatments
A challenge competition with a $50 million purse seeks new strategies to attack the global substance abuse epidemic, including personalized diagnostics and treatments.
-
A.I. Analytics Show Blood Test Detects Heart Disease
Data from three health repositories show a simple blood test reveals inherited and acquired genetic indicators, analyzed with artificial intelligence, to detect coronary heart disease.
-
Trial Okayed to Transplant Donated Islet Cells for Type 1 Diabetes
Health authorities in Sweden authorized the start of a clinical trial testing insulin-producing cells from donors engineered to prevent immune reactions in people with type 1 diabetes.
-
Generative A.I. Designs Novel Synthetic Proteins
Generate:Biomedicines describes its Chroma generative A.I. model in yesterday’s issue of the journal Nature, and is making the model available as open source through GitHub.
-
Cannabinoid Shown Safe, Lowers Agitation in Alzheimer’s Patients
A clinical trial in a small group of participants suggests a cannabinoid drug is safe and well-tolerated, and reduces agitation among patients with Alzheimer’s disease.
-
Start-Up Developing Precision Antibiotics for Resistant Bacteria
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds.
-
Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds
A developer of synthetic antibodies for neurodegenerative disorders delivered like gene therapies is raising €129 million ($US 138 million) in its first venture funding round.